Ardelyx Inc (NASDAQ:ARDX) CFO Mark Kaufmann sold 20,000 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $4.56, for a total transaction of $91,200.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of NASDAQ:ARDX traded down $0.05 during trading on Tuesday, reaching $4.50. The stock had a trading volume of 314,300 shares, compared to its average volume of 471,355. Ardelyx Inc has a 52 week low of $1.60 and a 52 week high of $6.78. The business’s 50-day moving average price is $4.54 and its 200 day moving average price is $3.27. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.79 and a quick ratio of 7.79. The stock has a market capitalization of $285.74 million, a PE ratio of -2.78 and a beta of 1.76.
Ardelyx (NASDAQ:ARDX) last posted its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.60 million. Analysts forecast that Ardelyx Inc will post -1.56 EPS for the current year.
A number of research analysts have commented on the stock. Svb Leerink raised their price target on shares of Ardelyx from $8.00 to $9.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 24th. Leerink Swann set a $9.00 price target on shares of Ardelyx and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Zacks Investment Research cut shares of Ardelyx from a “hold” rating to a “sell” rating in a research note on Monday. ValuEngine cut shares of Ardelyx from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 2nd. Finally, Piper Jaffray Companies set a $15.00 price target on shares of Ardelyx and gave the stock a “buy” rating in a research note on Thursday, September 12th. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. Ardelyx currently has an average rating of “Hold” and an average target price of $8.81.
Ardelyx, Inc, a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis.
Further Reading: Technical Analysis
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.